Overview
Our three main avenues for funding include grants, investment funds, and licensing agreements. We are preparing multiple grants to complete
our major pre-clinical (pre-FDA phase I) testing and hoping to
demonstrate the effectiveness of system to synergistic ally improve
other therapies. This year, we will pursue our first round of
investment funding and seek licensing agreements to spin off aspects
of our technology to other companies. Specifically, we can generate
substantial revenue by contracting to perform the R&D of larger
pharmaceutical corporations. The general trend that big pharmacies
have to outsourcing their development and testing provides an
opportunity for revenue and ability for us to refine our quality
control processes that are required for our own products.
|
